Breast Cancer Gene (BRCA) Mutations Treatment Market Outlook 2026–2035

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Breast Cancer Gene (BRCA) Mutations Treatment Market Expected To Change Between 2026 And 2030?

The breast cancer gene (brca) mutations treatment market size has witnessed robust growth over recent years. It is projected to expand from $5.01 billion in 2025 to $5.37 billion in 2026, at a compound annual growth rate (CAGR) of 7.2%. The increase observed in previous periods is attributable to factors such as limited awareness of brca mutations, restricted availability of genetic testing services, a continued reliance on conventional chemotherapy, the rising incidence of breast and ovarian cancer, and the progressive adoption of targeted therapies.

The breast cancer gene (brca) mutations treatment market size is anticipated to demonstrate significant growth over the next few years. It is projected to expand to $7 billion by 2030, achieving a compound annual growth rate (CAGR) of 6.9%. This growth throughout the forecast period can be attributed to several factors, including advancements in genomic sequencing technologies, an increase in PARP inhibitor indications, rising investment in precision oncology, greater adoption of combination therapies, and supportive reimbursement policies for genetic testing and targeted treatments. Major trends expected during this period include a rising uptake of genetic testing and early BRCA mutation screening, the growing utilization of PARP inhibitors in targeted therapy, an increasing focus on preventive and risk-reduction treatment strategies, the expansion of personalized and precision oncology approaches, and improved access to multimodal treatment options for BRCA-related cancers.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27231&type=smp

What Underlying Factors Are Accelerating The Growth Of The Breast Cancer Gene (BRCA) Mutations Treatment Market?

The heightened need for targeted therapies is anticipated to drive the expansion of the breast cancer gene (BRCA) mutation treatment market in the future. These therapies are medical interventions designed to precisely target cancer cells by concentrating on genetic alterations or specific proteins crucial for cancer development. The growing preference for targeted therapies stems mainly from their capacity to specifically attack diseased cells or molecules, thereby reducing harm to healthy tissues, which leads to enhanced treatment efficacy and fewer adverse reactions compared to conventional treatments. For breast cancer gene (BRCA) mutations, targeted therapies are beneficial as they provide precision medications that specifically tackle the genetic changes causing the illness, thereby improving patient results and lessening unwanted side effects. For example, in July 2023, a report from the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership body, indicated that there were 247 gene therapies in Phase II at the close of Q1 2023. This figure increased by 5%, reaching 260 by the end of Q2 2023. Consequently, the escalating demand for targeted therapies is propelling the expansion of the breast cancer gene (BRCA) mutation treatment market. An increasing emphasis on personalized medicine is projected to stimulate the growth of the breast cancer gene (BRCA) mutation treatment market moving ahead. Personalized medicine involves customizing medical care to match a patient’s distinct genetic, biological, and clinical attributes. The expansion of personalized medicine is fueled by progress in genetic testing, enabling treatments to be more accurately customized to each person’s biological profile. The heightened focus on personalized medicine is revolutionizing how BRCA gene mutations are managed. This is achieved by facilitating customized risk assessments, specific therapies like PARP inhibitors, and individual preventive approaches that maximize treatment effectiveness while reducing negative side effects, thereby ultimately enhancing results for patients suffering from hereditary breast and ovarian cancers. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, an increase from 6 in 2022. Among these newly approved personalized treatments for 2023 were seven cancer drugs and three for other diseases and conditions. Consequently, the increasing emphasis on personalized medicine is a key driver for the growth of the breast cancer gene (BRCA) mutation treatment market.

How Is The Breast Cancer Gene (BRCA) Mutations Treatment Market Structured Across Different Segments?

The breast cancer gene (brca) mutations treatment market covered in this report is segmented –

1) By Treatment Type: Targeted Therapies, Chemotherapy, Hormonal Therapy, Immunotherapy

2) By Indication: Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer

3) By Administration Route: Oral, Intravenous, Subcutaneous

4) By End-User: Hospitals, Clinics, Cancer Specialty Clinics

Subsegments:

1) By Targeted Therapies: Poly (ADP-Ribose) Polymerase Inhibitors, Mammalian Target Of Rapamycin Inhibitors, Cyclin-Dependent Kinase 4 And 6 Inhibitors, Tyrosine Kinase Inhibitors

2) By Chemotherapy: Platinum-Based chemotherapy, Anthracyclines, Taxanes, Antimetabolites

3) By Hormonal Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Selective Estrogen Receptor Degraders (SERDs), Luteinizing Hormone-Releasing Hormone (LHRH) Agonists

4) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Monoclonal Antibodies

Which Major Players Dominate The Breast Cancer Gene (BRCA) Mutations Treatment Market?

Major companies operating in the breast cancer gene (brca) mutations treatment market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Thermo Fisher Scientific Inc., AstraZeneca PLC, Novartis AG, GSK plc, Janssen Biotech Inc., Astellas Pharma Inc., Genentech Inc., Clovis Oncology Inc., Owkin Inc., Allarity Therapeutics Inc., VBL Therapeutics

Read the full breast cancer gene (brca) mutations treatment market report here:

https://www.thebusinessresearchcompany.com/report/breast-cancer-gene-brca-mutations-treatment-global-market-report

Which Region Is Projected To Dominate The Breast Cancer Gene (BRCA) Mutations Treatment Market During The Forecast Period?

North America was the largest region in the breast cancer gene (BRCA) mutations treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the breast cancer gene (brca) mutations treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Breast Cancer Gene (BRCA) Mutations Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27231&type=smp

Browse Through More Reports Similar to the Global Breast Cancer Gene (BRCA) Mutations Treatment Market 2026, By The Business Research Company

Converted Paper Products Market Report 2026

https://www.thebusinessresearchcompany.com/report/converted-paper-products-global-market-report

Decorative Concrete Market Report 2026

https://www.thebusinessresearchcompany.com/report/decorative-concrete-global-market-report

Concrete Materials Market Report 2026

https://www.thebusinessresearchcompany.com/report/concrete-materials-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795